Increased frequency of ESR1 mutation in metastatic breast cancer by dosing selective estrogen receptor modulator followed by aromatase inhibitor

In several recent studies on metastatic breast cancer (MBC), ligand binding domain mutations of the estrogen receptor, which is coded by the ESR1 gene, were induced by long-term endocrine therapy and resulted in acquired endocrine therapy resistance and poor outcomes. Knowledge of the association be...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncol Lett
Autores principales: Takeshima, Kaoru, Hayashida, Tetsu, Maeda, Hinako, Nakashoji, Ayako, Yokoe, Takamichi, Seki, Tomoko, Takahashi, Maiko, Kitagawa, Yuko
Formato: Artigo
Lenguaje:Inglês
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7377057/
https://ncbi.nlm.nih.gov/pubmed/32724363
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2020.11669
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares